TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05326490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: The dosage and administration of metformin hydrochloride remain unchanged before screening
Study: NCT05915689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial arm pull technique
Description: patient in supine position move the arm passively in abduction to the restricted barrier and pull the arm only enough traction was used to counterbalance the weight of the patient's arm. Stretch was hold until the fibers were released, and then, stretch was given again by increasing traction. This sequence was repeated until an end feel was reached. same procedure for flexion and scapular protraction and Horizontal-adduction. Repetition will be 4-5 reps. per set, 3 times per week for 18 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation technique
Description: The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the gleno humeral joint to palpate for motion and the subjects are directed to press the elbow towards therapist hand for shoulder abduction, internal rotation and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for six weeks with each repetition maintained for the duration of 7-10 second
Study: NCT05340361

Intervention type: DEVICE
Intervention: Optical coherence tomography-guided percutaneous coronary intervention
Description: OCT examination is performed using a frequency-domain OCT system (C7 Dragonfly OPTIS Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.

Intervention type: DEVICE
Intervention: Optical coherence tomography-guided Onyx family stent expansion
Description: 1. Expansion of 2.25, 3.0, and 4.0 mm Onyx family stent@ nominal pressure~2. OCT pullback~3. Expansion with over 0.5mm sized non-compliant balloon of each stent~4. OCT pullback~5. Expansion with over 1.0mm sized non-compliant balloon of each stent~6. OCT pullback~7. Expansion with over 1.25\~1.5mm sized non-compliant balloon of each stent~8. OCT pullback~9. Evaluation of polymer status with overexpansion assessed by an electric microscope
Study: NCT06465251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based CIMT
Description: Participants and their families will be required to attend clinic to practice 3 times (Monday, Wednesday and Friday) during the first week, 2 times (Monday and Friday) during the second week and once (Monday) during the 3rd week under the supervision of a trained research assistant. They will be allowed to practice exclusively at home during the 4th week under the supervision of their family members.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinic-based CIMT
Description: Participants in both groups will perform 5 tasks with the affected upper limb, each 100 times, making it 500 repetitions in total within a duration of 2 hours every day, five days a week for 4 weeks at home and in the clinic respectively. Details of the tasks to be performed are presented in table 1. We chose 2 hours because, patients with stroke can perform about 300 repetitions of tasks practice within one hour. Similarly, we chose 500 repetitions because the number of repetitions of tasks practice required for motor recovery ranges between 300 and 600 repetitions per day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will attend 45 minutes health talk provided by a research assistant twice in a week (Mondays and Fridays) in the clinic for 4 weeks. They will receive each talk in either a group of 3 or 5 patients. Similar control intervention was used in previous study
Study: NCT05931796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NON-ERAS pathway
Description: All patients received best of care practice, with standardization of preoperative and postoperative care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS pathway
Description: ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
Study: NCT05260905

Intervention type: BEHAVIORAL
Intervention: REHIT
Description: REHIt involves 10 minutes of unloaded cycling on a stationary bike, interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
Study: NCT05258773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401 (R-Azasetron Besylate)
Description: Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
Study: NCT05784779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH509
Description: Orally, once daily before bedtime (qhs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, once daily before bedtime (qhs)
Study: NCT06340048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HiCM-188 therapy
Description: Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HiCM-188 therapy
Description: Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HiCM-188 therapy
Description: Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
Study: NCT06127927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional Left Ventricular Assist System
Description: Interventional left ventricular assist system for cardiogenic shock patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional Left Ventricular Assist System
Description: Interventional left ventricular assist system for cardiogenic shock patients
Study: NCT06185829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurloeptanalgesic treatment
Description: Usual neuroleptanalgesic treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnoanalgesia
Description: Hypnoanalgesia
Study: NCT06170138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product 1 - Test product 2 - Comparator product
Description: Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product 1 - Test product 2 - Comparator product
Description: Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test product 1 - Test product 2 - Comparator product
Description: Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4).
Study: NCT06011343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral tofacitinib
Description: Association of tofacitinib and meglumine antimoniate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parenteral meglumine antimoniate
Description: Meglumine antimoniate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral meglumine antimoniate
Description: Meglumine antimoniate
Study: NCT04937244

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 5ALA exoscopic fluorescence filter
Description: Visualization of tumor tissue with 5ALA will be done in the operating room to localize neoplastic tissue. The operation will be conducted in a standard fashion uninfluenced by the imaging on the ORBEYE exoscope. The ORBEYE exoscope will be used with the blue light filter after tacking up dura upon first visualization of tumor tissue prior to direct resection. Images will be taken prior to, during and at the end of the planned resection. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. The ORBEYE exoscope or standard operating microscope (depending on surgeon preference) will then be used in the standard fashion of an operative microscope with a fluorescent filter, to assist with surgical resection as per the surgeon's preference. Resection will proceed according to current standard of care.
Study: NCT05351983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical biopsy of tumoral tissue for organoid generation
Description: In surgically-resectable lesions, tumoral samples will be collected from the main surgical specimens, before sending it for final pathological examination. Patients with metastatic disease, will be offered to undergo port-a-cath implantation for chemotherapy delivery and concomitant laparoscopic surgical excisional biopsy of suspicious metastatic lesions. Intraoperative frozen section will confirm the presence of malignant cells in the sample. Part of the specimen will be sent for assessment of contamination by bacterial and/or fungal flora by the Microbiology Laboratory. The remaining tumour sample will be sent for patient-derived organoid (PDO) formation. Two patients' blood samples will be retrieved in ethylenediaminetetraacetic acid (EDTA) tubes and will be sent with the surgical specimen. All patients will then receive the standard of care (SOC) treatment according to the clinical judgement of the oncologist in charge, always within the framework of the international guidelines.
Study: NCT06281067

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: full-physiology approach arm
Description: * All MB patients belonging to the full-physiology arm will undergo functional assessment of the intramural artery with basal Pd/Pa, FFR (after intravenous adenosine), RFR, CFR and IMR.~* In the presence of a negative functional assessment (Pd/Pa\> 0.92, FFR\> 0.80, RFR\> 0.89, CFR≥ 2.0 and IMR\< 25), FFR, CFR and IMR will be measured after inotropic stimulation with dobutamine (respectively FFR-d, CFR-d and IMR-d) to exalt the epicardial hemodynamic significance of MB or its impact on structural microvascular remodelling (impaired endothelium-independent vasodilatation).~* In the absence of epicardial hemodynamic significance (FFR-d\> 0.75) and structural microvascular dysfunction (CFR≥ 2.0 and IMR\< 25), ACH provocative test will be performed to evaluate the presence of epicardial or microvascular spasm (impaired endothelium-dependent vasodilatation).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: standard approach arm
Description: In the standard approach arm patients will undergo an angiographic evaluation of the tunnelled artery
Study: NCT00656240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 vehicle
Study: NCT05200403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole 2%
Description: The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.
Study: NCT06463691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Sonrotoclax, orally, 320 mg once daily following a weekly ramp-up schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3111
Description: Zanubrutinib, orally, 320 mg total daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD20
Description: CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.
Study: NCT04898920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
Study: NCT04981314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equinacea Arkopharma
Description: Echinacea hard caplets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo hard caplets
Study: NCT05837351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise -Running
Description: At baseline participants will wear a Fitbit for one week and attend the Runner's Assessment. After this the participant will begin to run 3 times per week for eight weeks. Every week, participation in a virtual support group with the physical therapist, research coordinator, and other research staff will be expected. Rest-activity cycles' data will be monitored; if at any point the runner is not able to complete 3 runs per week, participants will be encouraged to contact research staff the issues for this (such as medical problem or scheduling difficulty) and formulate plans to remediate the situation. Participants that would like to continue the treatment for an additional eight weeks will have additional data collected.~Participants will also wear the Fitbit through-out the study and complete surveys during the study and have blood drawn.
Study: NCT05845658

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
Study: NCT05692856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Description: Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
Study: NCT06343506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grassroots Ankle Flex
Description: This device can be used in an individual's home, without assistance, allowing more frequent stretching without increased visits to physical therapy. The Ankle Flex device is used to stretch patients into a dorsiflexion position by securing the foot to the base of the device and the shin to the leg strap attached to the pulley system. The patients can then pull the handle of the pulley system, giving them the mechanical advantage to gently mobilize their ankle into dorsiflexion with their foot firmly secured to the base of the device. This can allow for a deeper and more controlled stretch than previous stretching methods done during at home care.
Study: NCT05200403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle treatment
Description: The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometry device for children
Description: Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to \<2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.
Study: NCT05169684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT05144113

Intervention type: BEHAVIORAL
Intervention: Survey subjects to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.
Description: The following questionnaires will be answered by subjects:~Questionnaires:~Barriers to Physical Activity Questionnaire for People with Mobility Impairments (BPAQ-MI): measures barriers to physical activity across the intrapersonal and interpersonal domains.~Physical Activity and Disability Survey (PADS): measures physical activity for people with chronic neurological conditions.~Demographic and Mobility Questionnaire: Important information to inform on user and design needs and potential market for at home FES-row system.~Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)-(FES-row participants only): measures satisfaction with current FES-row system used in the ExPD Program.

Intervention type: BEHAVIORAL
Intervention: Survey subjects to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.
Description: The following questionnaires will be answered by subjects:~Questionnaires:~Barriers to Physical Activity Questionnaire for People with Mobility Impairments (BPAQ-MI): measures barriers to physical activity across the intrapersonal and interpersonal domains.~Physical Activity and Disability Survey (PADS): measures physical activity for people with chronic neurological conditions.~Demographic and Mobility Questionnaire: Important information to inform on user and design needs and potential market for at home FES-row system.~Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)-(FES-row participants only): measures satisfaction with current FES-row system used in the ExPD Program.
Study: NCT05843006

Intervention type: DIAGNOSTIC_TEST
Intervention: Examination and analysis of sweat and blood samples at baseline and at follow up
Description: Subjects will be assessed at baseline (as inpatients) and at 4-6 weeks at follow-up as outpatients according to standard operating procedures. Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Further examinations include measurement of left ventricular ejection fraction by echocardiography at baseline and blood pressure, heart rate, risk scores and health information will be collected at baseline and follow up.
Study: NCT05200403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometry device for children
Description: Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to \<2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometry device for adult caregivers
Description: Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometry device for adult caregivers
Description: Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.
Study: NCT05528315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-002
Description: ABX-002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-002
Description: ABX-002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-002
Description: ABX-002